Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2023-06-29 Transaction in Own Shar…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It includes detailed information about repurchase of shares, dates, prices, and confirmations of compliance with listing rules. The document is a regulatory disclosure about share repurchases and capital changes, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive data and confirmations. The content fits the category of 'Transaction in Own Shares' (POS), which covers company buybacks or sales of its own shares.
2023-06-29 English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) OF SANBEXIN SUBLINGUAL TABLETS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the acceptance of a New Drug Application (NDA) by the National Medical Products Administration (NMPA) in China. It provides details about the drug Sanbexin sublingual tablets, its clinical study results, and background information about the company and its partner Neurodawn. The document is an announcement of a business development event rather than a financial report, regulatory filing, or management discussion. It does not contain financial data, audit information, or shareholder voting results. It is not a report publication announcement since it is not about the release of a report but about a regulatory acceptance of a drug application. Therefore, the most appropriate classification is a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous announcements that do not fit other specific categories.
2023-06-28 English
GRANT OF AWARDS UNDER THE 2021 RSU SCHEME
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the grant of Restricted Share Units (RSUs) under the company's 2021 RSU Scheme. It details the number of RSUs granted, the grantees, vesting dates, performance targets, and clawback mechanisms. The announcement is made pursuant to a listing rule and includes definitions related to the RSU scheme. There is no indication that this is a full financial report, audit report, or earnings release. It is not a regulatory filing or report publication announcement since it contains substantive information about the share awards granted. The content fits the category of a Capital/Financing Update as it relates to equity compensation and share awards granted to employees, which affects the company's capital structure and share-based compensation plans.
2023-06-28 English
VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE
Transaction in Own Shares Classification · 100% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding a share repurchase program authorized by shareholders at the annual general meeting. It details the board's resolution to repurchase shares up to a certain amount and the conditions under which the repurchase will occur. The document does not contain financial statements or detailed financial analysis but is an announcement of a capital action (share repurchase). The document length is 3670 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits the category of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back its own shares.
2023-06-26 English
(UPDATED) FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2022
Notice of Dividend Amount Classification · 100% confidence The document is titled '(UPDATED) FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2022' and provides detailed information about the dividend amount, payment date, record date, ex-dividend date, and related shareholder information. It is an announcement specifically about the dividend payment for the financial year ended 2022. The document length is 3426 characters, which is relatively short and focused solely on dividend details. There is no financial statement or comprehensive report content. Therefore, this document fits the category of a Notice of Dividend Amount (DIV).
2023-06-15 English
(I) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 15, 2023 AND (II) PAYMENT OF FINAL DIVIDEND
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement from Simcere Pharmaceutical Group Limited regarding the poll results of their Annual General Meeting (AGM) held on June 15, 2023. It details the voting outcomes on various resolutions including adoption of audited financial statements, re-election of directors, appointment of auditors, and approval of dividend payment. It also includes information about the payment of the final dividend for the year ended December 31, 2022. The content is focused on the official results of shareholder votes at the AGM and dividend payment details, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not the full AGM materials or presentations, nor is it the annual report or financial statements themselves, but rather the official announcement of the voting results and dividend payment following the AGM.
2023-06-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.